Intangible Assets

MRKR does not show durable intangible assets in the provided metrics because TTM ROIC and ROCE are deeply negative, which indicates the company is not converting any proprietary asset base into economic returns versus peers.

The absence of disclosed 5-year margin or growth history in the supplied data limits evidence of persistent IP monetization, while peers with stronger clinical or commercial franchises typically show clearer return persistence.

As a development-stage biotech, any patent or regulatory exclusivity is inherently time-limited and has not yet translated into durable pricing power or margin resilience relative to better-established peers.

Switching Costs

MRKR appears to have minimal switching costs because the provided efficiency metrics show very weak capital productivity, which is inconsistent with a product or platform that customers must retain over time.

Unlike peers with entrenched diagnostics, software, or consumables workflows, MRKR does not show evidence of embedded customer dependence that would raise retention or reduce price sensitivity.

The very high cash conversion cycle suggests weak operating leverage and limited customer lock-in, which points to low durability of any switching advantage versus peers.

Network Effects

MRKR shows no evidence of network effects because the supplied metrics do not indicate user growth, ecosystem participation, or data flywheel benefits that would compound over time.

Compared with platform-based peers, MRKR lacks a self-reinforcing adoption loop that would make the product more valuable as more customers or partners use it.

Without observable network-driven retention or distribution advantages, any competitive position remains product-specific rather than ecosystem-based.

Cost Advantage

MRKR does not exhibit a cost advantage because negative ROIC and ROCE imply that unit economics are not yet strong enough to support lower-cost delivery than peers.

The low asset turnover suggests the asset base is not being used efficiently, which weakens the ability to spread fixed costs across meaningful revenue volume.

Relative to scaled competitors, MRKR lacks the purchasing, manufacturing, or commercialization scale needed to sustain structurally lower costs.

Efficient Scale

MRKR does not appear to benefit from efficient scale because the company is not operating in a clearly capacity-constrained niche where a small number of players can profitably dominate demand.

The negative return metrics indicate the current market structure is not producing the kind of stable, high-return economics that usually accompany efficient-scale moats.

Compared with peers that control specialized infrastructure or regulated bottlenecks, MRKR lacks evidence of a defensible scale position that would deter entry or preserve margins.

Overall Score

MRKR’s moat is weak versus peers because the supplied metrics show deeply negative capital returns, poor asset efficiency, and no observable evidence of switching costs, network effects, cost advantage, or efficient scale that would support durable pricing power or retention over 5–10 years.